THERAPEUTISCHE UMSCHAU最新文献

[Sarcoidosis from an immunological perspective - experience-based diagnosis and treatment with targeted therapies]. [从免疫学角度看结节病-基于经验的诊断和靶向治疗]。

IF 0.2

THERAPEUTISCHE UMSCHAU Pub Date : 2026-08-01 DOI: 10.23785/TU.2026.04.003

Aresh Farokhnia, Christian Friedrich Clarenbach, Lukas Frischknecht, Jakob Nilsson

引用次数: 0

[Innovative drug development: ethical and regulatory challenges]. [创新药物开发：伦理和监管挑战]。

IF 0.2

THERAPEUTISCHE UMSCHAU Pub Date : 2026-08-01 DOI: 10.23785/TU.2026.04.007

Thomas D Szucs

引用次数: 0

[Therapeutic apheresis in first-line treatment of hematological disorders - an evidence-based review]. [治疗性采血在血液病一线治疗中的应用——基于证据的综述]。

IF 0.2

THERAPEUTISCHE UMSCHAU Pub Date : 2026-08-01 DOI: 10.23785/TU.2026.04.005

Isabel Wiedl, Linet Muthoni Njue, Michael Daskalakis, Katarzyna Aleksandra Jalowiec

{"title":"[Therapeutic apheresis in first-line treatment of hematological disorders - an evidence-based review].","authors":"Isabel Wiedl, Linet Muthoni Njue, Michael Daskalakis, Katarzyna Aleksandra Jalowiec","doi":"10.23785/TU.2026.04.005","DOIUrl":"https://doi.org/10.23785/TU.2026.04.005","url":null,"abstract":"Introduction: Therapeutic apheresis (TA) is an important treatment for certain conditions. TA refers to various procedures in which either plasma (plasmapheresis) or specific blood cell fractions (cyta-pheresis) are removed. These include, among others, extracorporeal photopheresis (EP), erythrocytapheresis (EA), therapeutic plasma exchange (TPE), and therapeutic erythrocyte exchange (TEE). The indications for these procedures in specific diseases are published by the American Society for Apheresis (ASFA) as well as by hematology societies such as the American Society of Hematology (ASH) and the British Society of Haematology (BSH). There are only a few indications for therapeutic apheresis as first-line therapy for hematologic diseases, either as primary treatment or in combination with other therapies, for which strong evidence (Grade 1A-1C) exists. These indications include TPE for symptomatic hyperviscosity syndrome, hyperviscosity syndrome prophylaxis during rituximab therapy for Waldenström's macroglobulinemia, TEE for acute complications of sickle cell disease such as stroke and for the prophylaxis of such events, as well as the use of TPE for thrombotic thrombocytopenic purpura. Less well-known indications with strong evidence include the treatment of erythrocytosis in polycythemia vera and the treatment of iron overload in hereditary hemochromatosis using EA. Similarly, EP is an established treatment option for mycosis fungoides and Sézary syndrome. The aim of this paper is to summarize these indications.","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"83 4","pages":"139-145"},"PeriodicalIF":0.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148867144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunmodulation in Klinik und Praxis. 临床和实践中的免疫调节。

IF 0.2

THERAPEUTISCHE UMSCHAU Pub Date : 2026-08-01 DOI: 10.23785/TU.2026.04.001

Tämer El Saadany

引用次数: 0

[Melanoma - an overview of the disease and its treatment]. [黑色素瘤-疾病及其治疗概述]。

IF 0.2

THERAPEUTISCHE UMSCHAU Pub Date : 2026-08-01 DOI: 10.23785/TU.2026.04.004

Tamara El Saadany, Joanna Mangana

{"title":"[Melanoma - an overview of the disease and its treatment].","authors":"Tamara El Saadany, Joanna Mangana","doi":"10.23785/TU.2026.04.004","DOIUrl":"https://doi.org/10.23785/TU.2026.04.004","url":null,"abstract":"Introduction: Melanoma arises from malignant transformation of melanocytes and accounts for approximately 3500 new cases per year in Switzerland. The most important risk factors include intermittent UV exposure, fair skin, a high number of nevi, five or more atypical nevi, and a positive family history. The most common type is the superficial spreading melanoma, followed by the nodular type. Diagnosis is primarily clinical, for example using the ABCDE rule, and is supported by dermoscopy performed by dermatologists. If there is a suspicion, a narrow complete excision should be performed to confirm the diagnosis. Treatment options have improved drastically over the years, so nowadays there are indeed good chances of cure, even in a metastatic setting. Immunotherapy as well as targeted therapies have led to major breakthroughs. While adjuvant or neoadjuvant therapy is recommended in earlier stages of disease, PD-1 blockage plays a central role in metastatic disease, preferably in combination with anti-CTLA-4-antibody or, according to more recent data, with an anti-LAG-3-antibody. Targeted therapy also has an established role today in treatment, both in the adjuvant and curative settings. After successful treatment, regular follow-ups should be performed to detect relapses at an early stage.","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"83 4","pages":"133-138"},"PeriodicalIF":0.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148866871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Immune-related adverse events of immune checkpoint inhibitors]. [免疫检查点抑制剂免疫相关不良事件]。

IF 0.2

THERAPEUTISCHE UMSCHAU Pub Date : 2026-08-01 DOI: 10.23785/TU.2026.04.006

Tämer El Saadany, Tim Kahl, Roger von Moos

引用次数: 0

[Drug Discovery - A surge in innovation driven by technology and artificial intelligence]. [药物发现——由技术和人工智能驱动的创新浪潮]。

IF 0.2

THERAPEUTISCHE UMSCHAU Pub Date : 2026-08-01 DOI: 10.23785/TU.2026.04.002

Oliver Nayler, Martin Bolli

{"title":"[Drug Discovery - A surge in innovation driven by technology and artificial intelligence].","authors":"Oliver Nayler, Martin Bolli","doi":"10.23785/TU.2026.04.002","DOIUrl":"https://doi.org/10.23785/TU.2026.04.002","url":null,"abstract":"Introduction: Historically, the discovery of new pharmaceutical therapies has constituted a lengthy and cost-intensive process. Between the initial identification of a drug candidate and successful regulatory approval, 10 to 15 years commonly elapse, with development costs reaching the order of billions of dollars. Research activities, which are still largely empirical in nature, are frequently marked by setbacks, for example due to toxicological findings or insufficient efficacy in preclinical disease models. Technological breakthroughs, such as the sequencing of the human genome, have given rise to largely unmet expectations that medicines could be developed more rapidly and efficiently. Accordingly, expectations for the application of artificial intelligence (AI) in pharmaceutical research and development are high. Indeed, workflows in the preclinical phase are currently being fundamentally transformed by AI. In the following, the individual stages of preclinical research are analysed, and the potential applications of AI are described. In addition, selected critical aspects are discussed to realistically contextualize expectations regarding AI. As a result of the integration of AI, both preclinical and clinical research are undergoing profound transformation. There is justified hope that effective and safe therapies can finally be developed more rapidly and cost-efficiently.","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"83 4","pages":"122-125"},"PeriodicalIF":0.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148866376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Athlete's heart: role of cardiac imaging in the prevention of sudden cardiac death]. [运动员心脏：心脏成像在预防心源性猝死中的作用]。

IF 0.2

THERAPEUTISCHE UMSCHAU Pub Date : 2026-06-01

Leonard Weishaupt, Christine Attenhofer Jost, Ronny R Buechel, Stefano Caselli, Sarah Spalinger, Christian Schmied

引用次数: 0

[Coronary angiography: From cardiac catheterization to advanced interventional cardiovascular imaging]. 冠状动脉造影：从心导管造影到高级介入心血管造影。

IF 0.2

THERAPEUTISCHE UMSCHAU Pub Date : 2026-06-01 DOI: 10.23785/TU.2026.03.002

Thomas F Lüscher

引用次数: 0

[Inflammatory Heart Disease: The Role of Multimodality Cardiac Imaging in Myocarditis and Pericarditis]. 炎症性心脏病：多模态心脏成像在心肌炎和心包炎中的作用。

IF 0.2

THERAPEUTISCHE UMSCHAU Pub Date : 2026-06-01 DOI: 10.23785/TU.2026.03.005

Matthew Liam Wright, Konstantinos Bitos, Bettina Heidecker, Jeanette Schulz-Menger, Aju P Pazhenkottil

{"title":"[Inflammatory Heart Disease: The Role of Multimodality Cardiac Imaging in Myocarditis and Pericarditis].","authors":"Matthew Liam Wright, Konstantinos Bitos, Bettina Heidecker, Jeanette Schulz-Menger, Aju P Pazhenkottil","doi":"10.23785/TU.2026.03.005","DOIUrl":"https://doi.org/10.23785/TU.2026.03.005","url":null,"abstract":"Introduction: Myocarditis and pericarditis represent a broad spectrum of inflammatory heart diseases and are important differential diagnoses in patients presenting with chest pain, heart failure, or arrhythmias. Diagnosis is often challenging due to non-specific clinical presentation and biomarkers. Growing recognition of the clinical relevance of myocardial inflammation, together with accumulating evidence, has led to increased scientific and clinical attention. This is reflected in emerging concepts such as the introduction of the new term \"inflammatory myocardial syndrome (IMPS)\" in the recently published guidelines of the European Society of Cardiology (ESC). Notably, these are the first ESC guidelines to cover the full spectrum of inflammatory diseases of the myocardium and pericardium - marking an important paradigm shift in the field. Current ESC guidelines highlight the central role of multimodality cardiac imaging in the evaluation of myocardial inflammation. While echocardiography serves as a first-line tool, cardiac magnetic resonance imaging (CMR) is considered the non-invasive gold standard for tissue characterization. Nuclear imaging techniques such as positron emission tomography (PET) are increasingly relevant, particularly in specific entities such as cardiac sarcoidosis. This review highlights the practical role of multimodality imaging in the diagnostic work-up of myocardial inflammation, with emphasis on clinically relevant decision-making.","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"83 3","pages":"111-120"},"PeriodicalIF":0.2,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148319726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0